Immunome, Inc. (NASDAQ:IMNM) Receives $25.00 Consensus Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $26.3636.

IMNM has been the subject of a number of research reports. Wedbush reissued an “outperform” rating and issued a $21.00 price target on shares of Immunome in a report on Friday, November 7th. Evercore ISI started coverage on Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 target price for the company. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Finally, Guggenheim reiterated a “buy” rating and issued a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th.

Immunome Price Performance

IMNM stock opened at $22.64 on Thursday. The business has a fifty day moving average price of $17.11 and a 200 day moving average price of $12.39. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $25.30. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -7.67 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, equities analysts expect that Immunome will post -2.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Immunome by 43.4% in the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock valued at $28,987,000 after acquiring an additional 1,303,753 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Immunome by 34.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company’s stock valued at $4,135,000 after purchasing an additional 157,135 shares during the period. Deutsche Bank AG boosted its position in shares of Immunome by 38.2% in the 1st quarter. Deutsche Bank AG now owns 63,682 shares of the company’s stock worth $429,000 after purchasing an additional 17,607 shares during the last quarter. Swiss National Bank grew its stake in shares of Immunome by 67.5% during the first quarter. Swiss National Bank now owns 128,000 shares of the company’s stock worth $861,000 after purchasing an additional 51,600 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Immunome by 6.4% during the first quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock worth $191,000 after purchasing an additional 1,718 shares during the period. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.